Viewpoints

Myth: Oncology Patients Demand Inappropriate Interventions

Myth: Oncology Patients Demand Inappropriate Interventions

According to a JAMA study, only 8.7% of patients with cancer requested medical interventions and only 11.4% of those were deemed inappropriate.

Study Shows Inappropriate Medication Use Among Older Patients with Cancer

Study Shows Inappropriate Medication Use Among Older Patients with Cancer

A pharmacist-led medication assessment demonstrated a high prevalence of polypharmacy and potentially inappropriate medication use in seniors.

Feature Articles

Treating Hypercalcemia in Patients with Cancer

Treating Hypercalcemia in Patients with Cancer

Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer, and oncologists should know how to identify and treat it.

Lung Cancer Resources

More Lung Cancer Information

Where to Get Help to Quit Smoking

Patients can learn how to quick smoking cigarettes with the resources found in this informational fact sheet.

Smokeless Tobacco Effects, Harms and Cancer Risk

This patient fact sheet addresses common questions about the harms of smokeless, chewing tobacco.

Cigar Smoking Effects, Harms, and Cancer Risk

This fact sheets answers common questions, risks and health concerns for cigar smoking and cancer.

Lung Cancer: New Resources in Treatment Decision-Making

This fact sheet contains information on the different types of tumors as well as an overview of available biomarker tests.

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

This slideshow reviews drug information for XALKORI® (crizotinib), indicated for locally advanced or metastatic ALK+NSCLC.

Table of Contents

Slide 3: Indication, Dosage, ...

ZYKADIA™ (ceritinib)

ZYKADIA™ (ceritinib)

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table ...

Abraxane® (paclitaxel protein-bound particles) (albumin-bound) for NSCLC

Abraxane® (paclitaxel protein-bound particles) (albumin-bound) for NSCLC

This slideshow reviews Abraxane® (paclitaxel protein-bound particles (albumin-bound) for patients with non-small cell lung cancer.

Table of Contents

Slide 3: Indication, Dosage, ...

Advanced NSCLC: Best Treatment Option

Advanced NSCLC: Best Treatment Option

By Sandra Cuellar, PharmD, BCOP

A 63-year-old male is referred by his primary care physician for work-up of possible lung cancer. ...

A Rare Cause of Intestinal Dysmotility in a Patient with Small Cell Lung Cancer

A Rare Cause of Intestinal Dysmotility in a Patient with Small Cell Lung Cancer

By Tara Morrison, MD; Yu-Ning Wong, MD, MSCE

A 66-year-old African American man presented with a several month history of weight ...

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs